Navigation Links
Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy
Date:10/19/2009

Government hospitals have been Lotus's important direct sales channels. Any additional hospitals to increase the Company believes will have high entry barriers. Lotus plans to attempt to add new hospital channels in 2010.

Increase Quality Drugs Offering. Lotus's brand quality stems from its commitment to quality and efficacy of products. In case State Food and Drug Administration ("SFDA") is slow in approving any of the drugs in the pipeline, Lotus will attempt to produce drugs produced by third parties and sell them through its national sales force and network. By the end of 2010, Lotus currently intends to sell approximately 20 types of prescription drugs including its current 15 prescription drugs. Developing drugs to treat cardio-cerebrovascular, asthma and diabetes diseases remain the strategic focus in Lotus's pipeline development.

Geographic and Production Expansion. Production expansion is a part of Lotus's long term plan to tailor to its demand from drugs development. Lotus currently intends to start building the main body of the new facility in Inner Mongolia in 2010 subject to obtaining financing and self-generated capital. As part of the plan, a wholesales center would be established in Inner Mongolia to facilitate the growing market demand for pharmaceutical drugs in Inner Mongolia and five Northwestern provinces.

About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus's current drug development pipeline is focused on the treatment of cardio-cerebrovascular disease, asthma, and diabetes.

Safe Harbor Statement

This press release contain
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
2. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
3. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
4. Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
7. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
10. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
11. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 SoundConnect , an ... is proud to announce the addition of Adobe ... Connect’s elearning tools to quickly deploy and manage ... training tools for desktop and mobile learning solutions. ... the perfect online training solution, enabling organizations to ...
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
(Date:7/30/2014)... 30, 2014 Selexis SA , ... drug discovery and mammalian cell line development, announced today ... ™ will be presented at the 10th Annual ... September 8 – 10, 2014 at the Double Tree ... The following abstract will be presented during an oral ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... County Representatives Unveil State-of-the-Art Facility ... ... Officials from Novavax,Inc. (Nasdaq: NVAX ), the State ... new state-of-the-art vaccine production,facility at the company,s headquarters in Rockville, ...
... Total Revenues of $62.0 Million, Up 55 Percent over First Quarter ... 2007, - First ... Before Non-Cash Charges of $1.13 per Basic Share, ... per Diluted Share, SILVER SPRING, Md., May 1 United Therapeutics,Corporation (Nasdaq: UTHR ) ...
... Strategic Transactions Increase EUSA,s Focus on Late-Stage and Marketed ... ... Products, DOYLESTOWN, Pennsylvania and OXFORD, England, May 1 ,EUSA ... pain control and critical care, today announced that,it has divested ...
Cached Biology Technology:Novavax Opens Its First U.S. Vaccine Plant 2Novavax Opens Its First U.S. Vaccine Plant 3Novavax Opens Its First U.S. Vaccine Plant 4United Therapeutics Reports First Quarter 2008 Financial Results 2United Therapeutics Reports First Quarter 2008 Financial Results 3United Therapeutics Reports First Quarter 2008 Financial Results 4United Therapeutics Reports First Quarter 2008 Financial Results 5United Therapeutics Reports First Quarter 2008 Financial Results 6United Therapeutics Reports First Quarter 2008 Financial Results 7EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 2EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 3
(Date:7/30/2014)... paving the way for a breakthrough that may ... exposed to poisonous chemicalsparticularly those in pesticides and ... current issue of the journal ChemBioChem ... compounds commonly used in pesticides and warfare agents. ... of Engineering Associate Professor of Chemical and Biological ...
(Date:7/30/2014)... studying the potential effects of climate change on ... on the wrong factors, according to a new ... Conservation Society, University of Queensland, and other organizations. ... science is missing the point when it comes ... of climate change scientists focus on the "direct" ...
(Date:7/30/2014)... pleased to announce its new relationship with the International ... CINP will partner to publish International Journal of ... journal. , Alan Frazer, Editor-in-Chief of IJNP ... of OUP will further facilitate the goal for the ... leading journals within neuropsychopharmacology. The conversion of the ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2OUP to partner with the International College of Neuropsychopharmacology 2
... a research team from the National Institute of Standards ... has shown how to detect and monitor the tiny ... of an atomic force microscope probe, and in so ... of the instruments measurements under ambient conditions. Their recently ...
... have learned to manipulate the proportion of females and ... mapped the entire genome of a bacterium that infects ... published in PNAS, reveal extremely high frequencies of gene ... it is hoped that it will be possible to ...
... DC, March 25, 2009 - Critically endangered hawksbill turtles ... the Dominican Republic after a powerful government campaign cracked ... 99 percent of these souvenirs have been withdrawn or ... A 2006 survey carried out by TRAFFIC found ...
Cached Biology News:Making a point: Picoscale stability in a room-temperature AFM 2Gene exchange common among sex-manipulating bacteria 2Turtles no longer turned into souvenirs 2
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Src cDNA Expression Kit (wild type)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Biology Products: